Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021

Dow Jones07-15 22:47

Vertex Pharmaceuticals Incorporated $(VRTX)$ is currently at $474.81, down $1.50 or 0.31%

 

--Would be lowest close since June 23, 2026, when it closed at $468.42

--On pace for largest percent decrease since July 14, 2026, when it fell 0.82%

--Currently down seven consecutive days; down 10.34% over this period

--Longest losing streak since Aug. 16, 2021, when it fell for seven straight trading days

--Worst seven day stretch since the seven days ending Aug. 13, 2025, when it fell 16.17%

--Down 4.41% month-to-date

--Up 4.73% year-to-date

--Down 10.34% from its all-time closing high of $529.59 on July 6, 2026

--Up 1.12% from 52 weeks ago (July 16, 2025), when it closed at $469.55

--Down 10.34% from its 52-week closing high of $529.59 on July 6, 2026

--Up 29.54% from its 52-week closing low of $366.54 on Aug. 8, 2025

--Traded as low as $469.60; lowest intraday level since June 23, 2026, when it hit $463.76

--Down 1.41% at today's intraday low

--10th least active stock in the Nasdaq 100 today

 

All data as of 10:45:14 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

July 15, 2026 10:47 ET (14:47 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment